These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 29741222)

  • 1. Chemotherapy-induced alopecia: A novel observation.
    Rossi A; Fortuna MC; Caro G; Pigliacelli F; D'Arino A; Carlesimo M
    Australas J Dermatol; 2019 Feb; 60(1):e61-e62. PubMed ID: 29741222
    [No Abstract]   [Full Text] [Related]  

  • 2. Adjuvant cyclophosphamide, methotrexate, and fluorouracil versus fluorouracil, epirubicin, and cyclophosphamide chemotherapy in premenopausal women with axillary node-positive operable breast cancer: results of a randomized trial. The International Collaborative Cancer Group.
    Coombes RC; Bliss JM; Wils J; Morvan F; Espié M; Amadori D; Gambrosier P; Richards M; Aapro M; Villar-Grimalt A; McArdle C; Pérez-López FR; Vassilopoulos P; Ferreira EP; Chilvers CE; Coombes G; Woods EM; Marty M
    J Clin Oncol; 1996 Jan; 14(1):35-45. PubMed ID: 8558217
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemotherapy-induced hair loss.
    Tierney A; Taylor J
    Nurs Stand; 1991 Jun 12-18; 5(38):29-31. PubMed ID: 1907174
    [No Abstract]   [Full Text] [Related]  

  • 4. Docetaxel followed by fluorouracil/epirubicin/cyclophosphamide as neoadjuvant chemotherapy for patients with primary breast cancer.
    Iwata H; Sato N; Masuda N; Nakamura S; Yamamoto N; Kuroi K; Kurosumi M; Tsuda H; Akiyama F; Ohashi Y; Toi M
    Jpn J Clin Oncol; 2011 Jul; 41(7):867-75. PubMed ID: 21719750
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Persistent pain, sensory disturbances and functional impairment after adjuvant chemotherapy for breast cancer: cyclophosphamide, epirubicin and fluorouracil compared with docetaxel + epirubicin and cyclophosphamide.
    Andersen KG; Jensen MB; Kehlet H; Gärtner R; Eckhoff L; Kroman N
    Acta Oncol; 2012 Nov; 51(8):1036-44. PubMed ID: 22676048
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A prospective randomized trial comparing epirubicin monochemotherapy to two fluorouracil, cyclophosphamide, and epirubicin regimens differing in epirubicin dose in advanced breast cancer patients. The French Epirubicin Study Group.
    J Clin Oncol; 1991 Feb; 9(2):305-12. PubMed ID: 1988577
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glucose intolerance during adjuvant chemotherapy for breast cancer.
    Hickish T; Astras G; Thomas P; Penfold S; Purandare L; Hickish TF; Kerr D
    J Natl Cancer Inst; 2009 Apr; 101(7):537. PubMed ID: 19318627
    [No Abstract]   [Full Text] [Related]  

  • 8. A randomized trial of minoxidil in chemotherapy-induced alopecia.
    Duvic M; Lemak NA; Valero V; Hymes SR; Farmer KL; Hortobagyi GN; Trancik RJ; Bandstra BA; Compton LD
    J Am Acad Dermatol; 1996 Jul; 35(1):74-8. PubMed ID: 8682968
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Docetaxel plus carboplatin versus EC-T as adjuvant chemotherapy for triple-negative breast cancer: safety data from a phase III randomized open-label trial].
    Yuan P; Xu BH; Wang JY; Ma F; Li Q; Zhang P; Fan Y; Li Q; Wang WM
    Zhonghua Zhong Liu Za Zhi; 2012 Jun; 34(6):465-8. PubMed ID: 22967451
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of Scalp Cooling in Preventing Chemotherapy-Induced Alopecia in Breast Cancer Patients Receiving Adjuvant Docetaxel and Cyclophosphamide Chemotherapy.
    Cigler T; Isseroff D; Fiederlein B; Schneider S; Chuang E; Vahdat L; Moore A
    Clin Breast Cancer; 2015 Oct; 15(5):332-4. PubMed ID: 25749072
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant dose-dense sequential chemotherapy with epirubicin, CMF, and weekly docetaxel is feasible and safe in patients with operable breast cancer.
    Fountzilas G; Pectasides D; Christodoulou C; Timotheadou E; Economopoulos T; Papakostas P; Papadimitriou C; Gogas H; Efstratiou I; Skarlos D
    Med Oncol; 2006; 23(4):479-88. PubMed ID: 17303906
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epirubicin versus mitoxantrone in combination chemotherapy for metastatic breast cancer.
    Pavesi L; Preti P; Da Prada G; Pedrazzoli P; Poggi G; Robustelli della Cuna G
    Anticancer Res; 1995; 15(2):495-501. PubMed ID: 7763029
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Neoadjuvant treatment for locally advanced breast cancer. Comparison of two schemes based on docetaxel-epirubicin vs. 5-fluorouracil-epirubicin-cyclophosphamide].
    Cortés-Flores AO; Morgan-Villela G; Castro-Cervantes JM; Vázquez-Camacho G; Fuentes-Orozco C; González-Ojeda A
    Cir Cir; 2008; 76(1):23-8. PubMed ID: 18492416
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dose-intensive epirubicin-based chemotherapy is superior to an intensive intravenous cyclophosphamide, methotrexate, and fluorouracil regimen in metastatic breast cancer: a randomized multinational study.
    Ackland SP; Anton A; Breitbach GP; Colajori E; Tursi JM; Delfino C; Efremidis A; Ezzat A; Fittipaldo A; Kolaric K; Lopez M; Viaro D;
    J Clin Oncol; 2001 Feb; 19(4):943-53. PubMed ID: 11181656
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epirubicin Plus Cyclophosphamide Followed by Docetaxel Versus Epirubicin Plus Docetaxel Followed by Capecitabine As Adjuvant Therapy for Node-Positive Early Breast Cancer: Results From the GEICAM/2003-10 Study.
    Martín M; Ruiz Simón A; Ruiz Borrego M; Ribelles N; Rodríguez-Lescure Á; Muñoz-Mateu M; González S; Margelí Vila M; Barnadas A; Ramos M; Del Barco Berron S; Jara C; Calvo L; Martínez-Jáñez N; Mendiola Fernández C; Rodríguez CA; Martínez de Dueñas E; Andrés R; Plazaola A; de la Haba-Rodríguez J; López-Vega JM; Adrover E; Ballesteros AI; Santaballa A; Sánchez-Rovira P; Baena-Cañada JM; Casas M; del Carmen Cámara M; Carrasco EM; Lluch A
    J Clin Oncol; 2015 Nov; 33(32):3788-95. PubMed ID: 26416999
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neoadjuvant 5-fluorouracil, epirubicin and cyclophosphamide chemotherapy followed by docetaxel in refractory patients with locally advanced breast cancer.
    Heller W; Mazhar D; Ward R; Sinnett HD; Lowdell C; Phillips R; Shousha S; Fayaz A; Palmieri C; Coombes RC
    Oncol Rep; 2007 Jan; 17(1):253-9. PubMed ID: 17143506
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High pathologic complete response in HER 2-positive locally advanced breast cancer after primary systemic chemotherapy with weekly docetaxel and epirubicin.
    Chen SC; Chang HK; Lin YC; Hsueh S; Cheung YC; Leung WM; Tsai CS; Lo YF; Tsai HP; Shen SC; Chen MF
    Jpn J Clin Oncol; 2008 Feb; 38(2):99-105. PubMed ID: 18270380
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Dose dense chemotherapy in the postoperative adjuvant treatment for breast cancer].
    Zhou YD; Sun Q; Huan HY; Mao F; Guan JH
    Zhonghua Zhong Liu Za Zhi; 2007 Apr; 29(4):316-8. PubMed ID: 17760265
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mitoxantrone, 5-fluorouracil and cyclophosphamide in advanced breast cancer.
    Martoni A; Rani P; Ercolino L; Canova N; Pannuti F
    Chemioterapia; 1988 Oct; 7(5):345-9. PubMed ID: 3224403
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anthracycline-induced cardiomyopathy in siblings with early breast cancer.
    Young AC; Mercer B; Perren TJ; Dodwell D
    Ann Oncol; 2011 Jul; 22(7):1692. PubMed ID: 21555361
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.